Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andriy Krendyukov

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Pharmaceutical Medicine|February 29, 2020
Critical Factors Shaping Strategy Development of an Innovative Medicine in OncologyAndriy Krendyukov, Sreekanth Gattu
Pharmaceutical Medicine|June 20, 2020
Evolving Communication with Healthcare Professionals in the Pharmaceutical Space: Current Trends and Future PerspectivesAndriy Krendyukov, Dévi Nasy
Pharmaceutical Medicine|March 13, 2022
Medical Affairs and Innovative Medicinal Product Strategy DevelopmentAndriy Krendyukov, Dévi Nasy
Cancer Management and Research|October 1, 2019
Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignanciesAndriy Krendyukov, Christian Gieffers
Future Oncology (London, England)|March 6, 2019
The evolution of value with filgrastim in oncologyPaul Cornes, Andriy Krendyukov
Critical Reviews in Oncology/Hematology|August 14, 2019
Biosimilars in oncology: A decade of experience with granulocyte colony-stimulating factor and its implications for monoclonal antibodiesAndriy Krendyukov, Martin Schiestl
Frontiers in Oncology|March 25, 2021
Value of Adaptive Trials and Surrogate Endpoints for Clinical Decision-Making in Rare CancersAndriy Krendyukov, Sanjay Singhvi, Markus Zabransky
European Journal of Cancer (Oxford, England : 1990)|December 12, 2017
Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patientsEdoardo Botteri, Andriy Krendyukov, Giuseppe Curigliano
European Journal of Cancer Care|April 11, 2019
Treatment patterns and outcomes in patients with non-small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy-induced/febrile neutropaenia: Results from the MONITOR-GCSF studyMatti Aapro, Andriy Krendyukov, Nadja Höbel, et al.
European Journal of Haematology|November 25, 2017
MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxisPere Gascón, Andriy Krendyukov, Nadja Höbel, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Pharmaceutical Medicine|February 29, 2020
Critical Factors Shaping Strategy Development of an Innovative Medicine in OncologyAndriy Krendyukov, Sreekanth Gattu
Pharmaceutical Medicine|June 20, 2020
Evolving Communication with Healthcare Professionals in the Pharmaceutical Space: Current Trends and Future PerspectivesAndriy Krendyukov, Dévi Nasy
Pharmaceutical Medicine|March 13, 2022
Medical Affairs and Innovative Medicinal Product Strategy DevelopmentAndriy Krendyukov, Dévi Nasy
Cancer Management and Research|October 1, 2019
Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignanciesAndriy Krendyukov, Christian Gieffers
Future Oncology (London, England)|March 6, 2019
The evolution of value with filgrastim in oncologyPaul Cornes, Andriy Krendyukov
Critical Reviews in Oncology/Hematology|August 14, 2019
Biosimilars in oncology: A decade of experience with granulocyte colony-stimulating factor and its implications for monoclonal antibodiesAndriy Krendyukov, Martin Schiestl
Frontiers in Oncology|March 25, 2021
Value of Adaptive Trials and Surrogate Endpoints for Clinical Decision-Making in Rare CancersAndriy Krendyukov, Sanjay Singhvi, Markus Zabransky
European Journal of Cancer (Oxford, England : 1990)|December 12, 2017
Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patientsEdoardo Botteri, Andriy Krendyukov, Giuseppe Curigliano
European Journal of Cancer Care|April 11, 2019
Treatment patterns and outcomes in patients with non-small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy-induced/febrile neutropaenia: Results from the MONITOR-GCSF studyMatti Aapro, Andriy Krendyukov, Nadja Höbel, et al.
European Journal of Haematology|November 25, 2017
MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxisPere Gascón, Andriy Krendyukov, Nadja Höbel, et al.
Pageof 4